Assignee
IMPACT THERAPEUTICS SHANGHAI INC
CN·7 granted patents·13 pending applications·2 citations·filing 2018–2025
Top patents by PatentIndex Score
20 records- 0183US11345711B28,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-onesIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Granted May 31, 2022·1 cites·13 claims
- 0275US11345710B2Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2018·Granted May 31, 2022·1 cites·20 claims
- 0367US2025320219A1Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0461US12544378B2Solid pharmaceutical formulation of PARP inhibitors and use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Granted Feb 10, 2026·0 cites·14 claims
- 0560US2025215013A1Substituted tricyclic compounds as parp inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0659US12479848B2Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Granted Nov 25, 2025·0 cites·19 claims
- 0759US2024368169A1Substituted tricyclic compounds as parp inhibitors and use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0858US2024409538A1Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0958US2024082166A1Oral capsule of parp inhibitor and preparation method thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1057US2023263801A1Combination therapy of parp inhibitorsIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1157US2024208969A1Substituted fused bicyclic compounds as parp inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1256US2024059695A1SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOFIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1356US2024124464A1Substituted fused bicyclic compound as kinase inhibitor and use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1454US12492197B23,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Granted Dec 9, 2025·0 cites·20 claims
- 1552US2024091233A1Use of wee1 kinase inhibitors in the treatment of cancerIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1651US2022354859A1Substituted imidazoquinoxaline compounds and uses thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1751US2022259211A1Substituted pyrazoloquinazolinone compounds and application thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1851US2024010655A1Dihydroimidazo pyrimido pyrimidinone compoundIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1946US12534454B2Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Granted Jan 27, 2026·0 cites·16 claims
- 2046US11547703B2Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2018·Granted Jan 10, 2023·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when IMPACT THERAPEUTICS SHANGHAI INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →